-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2022 to Q2 2023.
- Ambrx Biopharma Cayman, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2023 was -$17.8M, a 38.2% increase year-over-year.
- Ambrx Biopharma Cayman, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$78M, a 14.6% decline from 2021.
- Ambrx Biopharma Cayman, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$68.1M, a 312% decline from 2020.
- Ambrx Biopharma Cayman, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$16.5M, a 17.5% increase from 2019.
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)